Avid Bioservices Inc (CDMO)

[biopharm]

Here is a paper that Freeeman published in May 2010 in Immunological Reviews.

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2914464/

TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity.

Freeman GJ, Casasnovas JM, Umetsu DT, DeKruyff RH.
Department of Medical Oncology, Dana-Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, MA, USA.

Abstract
The TIM (T cell/transmembrane, immunoglobulin, and mucin) gene family plays a critical role in regulating immune responses, including allergy, asthma, transplant tolerance, autoimmunity, and the response to viral infections. The unique structure of TIM immunoglobulin variable region domains allows highly specific recognition of phosphatidylserine (PtdSer), exposed on the surface of apoptotic cells. TIM-1, TIM-3, and TIM-4 all recognize PtdSer but differ in expression, suggesting that they have distinct functions in regulating immune responses. TIM-1, an important susceptibility gene for asthma and allergy, is preferentially expressed on T-helper 2 (Th2) cells and functions as a potent costimulatory molecule for T-cell activation. TIM-3 is preferentially expressed on Th1 and Tc1 cells, and generates an inhibitory signal resulting in apoptosis of Th1 and Tc1 cells. TIM-3 is also expressed on some dendritic cells and can mediate phagocytosis of apoptotic cells and cross-presentation of antigen. In contrast, TIM-4 is exclusively expressed on antigen-presenting cells, where it mediates phagocytosis of apoptotic cells and plays an important role in maintaining tolerance. TIM molecules thus provide a functional repertoire for recognition of apoptotic cells, which determines whether apoptotic cell recognition leads to immune activation or tolerance, depending on the TIM molecule engaged and the cell type on which it is expressed.

Gordon Freeman is all charged up about PS Targeting and he is back and hopefully given the green light to discuss it, or maybe someone else will beat him to it.

---------------------------------------------------

ACI™-Washington, D.C. Program Schedule
Friday August 7, 2015

...
...
Session I: Principles of Tumor Immunology

8:50 a.m. – 9:15 a.m.
Basic Mechanisms of Tumor Immune Suppression
Gordon J. Freeman, PhD - Dana-Farber Cancer Institute

...
...
Session II: Major Approaches to Tumor Immunotherapy – What the Clinician Needs to Know

11:40 a.m. – 12:05 p.m.
Is There a Role for Combination Radiation Therapy and Immunotherapy?
Michael Postow, MD - Memorial Sloan-Kettering Cancer Center

...
..
http://www.sitcancer.org/sitc-meetings/aci2015/dc/schedule